T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2476
Amerant Bancorp
AMTB
$1.14B
| $407K | ﹤0.01% |
20,843
+1,318
| +7% | +$24.5K |
|
2477
iShares MSCI Taiwan ETF
EWT
$11.6B
| $406K | ﹤0.01% |
+6,380
| New | +$411K |
|
2478
Lyell Immunopharma
LYEL
$337M
| $405K | ﹤0.01% |
13,128
| – | – |
|
2479
Lightwave Logic
LWLG
$1.12B
| $402K | ﹤0.01% |
123,784
-47,741
| -28% | -$212K |
|
2480
MediaAlpha
MAX
$813M
| $402K | ﹤0.01% |
31,014
+2,238
| +8% | +$27.3K |
|
2481
Shutterstock
SSTK
$217M
| $401K | ﹤0.01% |
20,970
+2,366
| +13% | +$50.6K |
|
2482
Ramaco Resources Class A
METC
$667M
| $400K | ﹤0.01% |
22,178
+6,843
| +45% | +$180K |
|
2483
Sabre
SABR
$892M
| $400K | ﹤0.01% |
294,020
+20,236
| +7% | +$34.9K |
|
2484
Heritage Insurance Holdings
HRTG
$989M
| $399K | ﹤0.01% |
13,635
+1,707
| +14% | +$46.1K |
|
2485
Community Health Systems
CYH
$419M
| $397K | ﹤0.01% |
127,022
+8,940
| +8% | +$30.1K |
|
|
HTB
2486
HomeTrust Bancshares
HTB
$837M
| $395K | ﹤0.01% |
9,183
+758
| +9% | +$31.3K |
|
2487
Graham Corp
GHM
$1.3B
| $394K | ﹤0.01% |
6,124
+617
| +11% | +$37.2K |
|
2488
ARS Pharmaceuticals
SPRY
$606M
| $394K | ﹤0.01% |
33,788
| – | – |
|
2489
Covenant Logistics
CVLG
$880M
| $391K | ﹤0.01% |
17,705
+1,072
| +6% | +$22.5K |
|
2490
Genesco
GCO
$394M
| $390K | ﹤0.01% |
15,706
| – | – |
|
|
JBIO
2491
Jade Biosciences
JBIO
$1.51B
| $389K | ﹤0.01% |
25,169
+8,913
| +55% | +$105K |
|
2492
Pure Cycle
PCYO
$273M
| $388K | ﹤0.01% |
35,295
| – | – |
|
2493
Willis Lease Finance
WLFC
$1.15B
| $388K | ﹤0.01% |
8,574
+699
| +9% | +$30.1K |
|
2494
Mativ Holdings
MATV
$667M
| $387K | ﹤0.01% |
31,803
+3,334
| +12% | +$39.3K |
|
2495
Vuzix
VUZI
$220M
| $387K | ﹤0.01% |
102,349
| – | – |
|
2496
Erasca
ERAS
$6.25B
| $386K | ﹤0.01% |
103,503
+9,923
| +11% | +$27.9K |
|
|
NXRT
2497
NexPoint Residential Trust
NXRT
$636M
| $386K | ﹤0.01% |
12,793
+942
| +8% | +$28.9K |
|
2498
Orion
OEC
$360M
| $386K | ﹤0.01% |
72,933
+43,600
| +149% | +$237K |
|
2499
PetMed Express
PETS
$43.4M
| $385K | ﹤0.01% |
120,055
| – | – |
|
|
AIOT
2500
PowerFleet Inc
AIOT
$421M
| $385K | ﹤0.01% |
72,259
+6,386
| +10% | +$32.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.